$CRL

Parisotto Shannon M sold $1.3M of CRL

Parisotto Shannon M (CEVP, Disc & Safety Assessment) sold 5,046 shares of CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) at $263.00 ($1.33M total) on 2026-08-05 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Parisotto Shannon M
Published Aug 6, 2026, 8:49 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 6, 2026, 9:46 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CRL
Neutral
high confidence
Mentioned
$CRL
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CRLNeutralLow
01

Why it matters

The newest fact is the specific sale size, price ($263/share), and that it was executed under a pre-arranged 10b5-1 plan.

02

Market read

Traders may note the disclosed insider sale, but the 10b5-1 framing makes it less likely to drive a durable repricing.

03

What to watch

The filing does not indicate why the sale occurred, whether it was part of a broader planned schedule, or whether other insiders executed offsetting buys.

Relevance 5/10Novelty 3/10Timing: Filed on 2026-08-06, disclosing an insider sale executed 2026-08-05.

Background

The article is an SEC Form 4 insider transaction disclosure for Charles River Laboratories International, Inc.

Company-level read

Ticker impact

$CRLNeutralHigh confidence
Context

SEC Form 4 shows CRL officer Parisotto Shannon M sold 5,046 shares on 2026-08-05 for about $1.33M under a 10b5-1 plan.

Expected impact

Low likelihood of a sustained price move from this filing alone; any reaction is likely muted and short-lived.

Evidence & confidence

The transaction is an open-market sale by an officer and explicitly states a pre-arranged Rule 10b5-1 plan, which typically reduces interpretive value versus discretionary selling.

Market effects

Minimal. Insider 10b5-1 sales do not materially change biotech/life-science services demand expectations.

None.

None.

Counterpoint

Even with 10b5-1, clustered insider selling can coincide with internal risk management or tax planning, which some traders may still treat as a mild negative sentiment input.

Key entities

  • CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

    Subject of the Form 4 insider transaction disclosure.

  • Parisotto Shannon M

    Officer (CEVP, Disc & Safety Assessment) who sold shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CRLHigh

Charles River Labs Stock Climbs As Analysts Boost Targets

Charles River Laboratories (CRL) stock rose 11.27% on strong earnings and analyst upgrades. The company reported $1.00B revenue, $150.8M EBITDA, and $148.62M free cash flow. Analysts raised price targets to $320-$357, citing long-term growth plans and margin expansion. CRL's 'Pathway to Purpose' targets 5-7% revenue CAGR and 24% operating margins by 2030.

$CRLHigh

Charles River (CRL) Stock Climbs As Wall Street Turns Bullish

Charles River Laboratories (CRL) stock rose 8.5% on regulatory relief and bullish sentiment. The company's stock broke out of a $290–$310 range, closing near $343. CRL reported $4.0B in annual revenue, with a 32.7% gross margin. Analysts raised price targets, citing margin expansion and growth plans. The next earnings call is scheduled for November 4, 2026.

$CRLHighAI 8/10

Why is Charles River Laboratories stock surging today?

Charles River Laboratories (CRL) stock rose 5.7% to $293.22 after its Investor Day, where it unveiled a 'Pathway to Purpose' strategy and raised its 2026 financial outlook. The company set 2030 targets of 5-7% annual organic revenue growth and a 24% non-GAAP operating margin, while reaffirming and upgrading its 2026 guidance. The move was driven by company-specific developments, as the broader market declined.

$CRLMed

Why Charles River Laboratories (CRL) Stock Is Trading Up Today

Charles River Laboratories (CRL) shares rose 3.6% after launching rapid cell banking programs, reducing production time by 40% compared to industry standards. The company aims to improve product quality and regulatory readiness. Shares closed at $281.70, up 3% from the previous close. CRL's stock has seen significant volatility, with a 38.1% gain year-to-date.